A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

Three patient deaths linked to gene therapies developed by Sarepta Therapeutics (SRPT) have drawn FDA scrutiny on the viral ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...

Bank of America downgraded Sarepta Therapeutics (NASDAQ:SRPT) to Underperform from Neutral on Wednesday, becoming the latest ...

Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

Morgan Stanley downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Equalweight on Monday, slashing its price target to $40.00 from $113.00 following safety concerns.The stock, which ...

Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental ...